SCHEMBL158595

SCHEMBL158595

C=CC(C)(C)OC[C@@H]1O[C@H](O[C@H]2C3=C([C@H](C)COC(C)=O)C[C@@H](O)[C@]3(C)/C=C3/[C@H](COC)CC[C@@H]3[C@@H](C)[C@@H]2O)[C@@H](O)[C@H](OC(C)=O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
YWHAZ P63104 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14530930 1.00 YWHAZ (1.00) YWHAZ
SCHEMBL14497663 1.00 YWHAZ (1.00) YWHAZ
SCHEMBL13770407 1.00 YWHAZ (1.00) YWHAZ
SCHEMBL14749536 1.00 YWHAZ (1.00) YWHAZ
SCHEMBL29914208 1.00 YWHAZ (1.00) YWHAZ
SCHEMBL14749541 0.94 YWHAZ (0.90) YWHAZ
SCHEMBL14749566 0.94 YWHAZ (0.89) YWHAZ
SCHEMBL26598089 0.94 YWHAZ (0.88) YWHAZ
SCHEMBL13764968 0.90 YWHAZ (0.81) YWHAZ
SCHEMBL26560757 0.89 YWHAZ (0.80) YWHAZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP claimed
US-20240276934-A1 LEAF VEIN ABSORPTION METHOD AND FUNCTIONAL MODIFICATION MATERIAL FOR PLANT NATIONAL CHENG KUNG UNIVERSITY (TW) 2024-08-22 US claimed
US-20240174708-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMBAGON THERAPEUTICS INC (US) 2024-05-30 US claimed
WO-2024069235-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2024-04-04 WO claimed
US-20240052015-A1 INDUCIBLE SIGNALLING PROTEIN Quell Therapeutics Limited (GB) 2024-02-15 US claimed
EP-4267601-A1 INDUCIBLE SIGNALLING PROTEIN Quell Therapeutics Limited (GB) 2023-11-01 EP claimed
WO-2023099886-A1 SIGNALLING PROTEIN Quell Therapeutics Limited (GB) 2023-06-08 WO claimed
CN-114989997-A Recombinant yarrowia lipolytica strain for high yield of sclareol and construction method and application thereof 南京工业大学 2022-09-02 CN claimed
WO-2022136874-A1 INDUCIBLE SIGNALLING PROTEIN Quell Therapeutics Limited (GB) 2022-06-30 WO claimed
EP-3852608-A1 COMPOSITIONS AND METHODS FOR GLAUCOMA Aufbau Medical Innovations Limited (IE) 2021-07-28 EP claimed
EP-1599497-B1 CRYSTAL STRUCTURE OF THE TERNARY COMPLEX OF 14-3-3, FUSICOCCIN, AND PLASMA MEMBRANE ATPASE AND METHODS FOR DESIGNING NEW HERBICIDES MAX PLANCK GESELLSCHAFT (DE) 2010-08-04 EP claimed
US-20090291905-A1 FUNGAL PHYTOTOXIN FUSICOCCIN FOR THE TREATMENT AND DIAGNOSIS OF COAGULATION-CORRELATED PATHOLOGIES UNIVERSITA' DEGLI STUDI DI ROMA "TOR VEGATA" (IT) 2009-11-26 US claimed
US-20090215708-A1 Treatment of Sexual Dysfunction with Proton Pump Agonists GALER BRADLEY STUART 2009-08-27 US claimed
US-7563825-B1 Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation CHOONGWAE PHARMA CORPORATION (KR) 2009-07-21 US claimed
US-7521538-B2 Crystal structure of the ternary complex of 14-3-3/Fusicoccin/PMA and methods for designing new herbicides MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2009-04-21 US claimed
CN-101278616-A Drought-resistant salt-alkali tolerant corn seed coating agent XINJIANG GREENLAND SCIENCE AND (CN) 2008-10-08 CN claimed
US-20070287629-A1 Crystal structure of the ternary complex of 14-3-3/fusicoccin/pma and methods for designing new herbicides MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2007-12-13 US claimed
EP-1599497-A2 CRYSTAL STRUCTURE OF THE TERNARY COMPELEX OF 14-3-3, FUSICOCCIN, AND PLASMA MEMBRANE ATPASE AND METHODS FOR DESIGNING NEW HERBICIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin (DE) 2005-11-30 EP claimed
EP-0847241-B1 INFLUENCING THE ACTIVITY OF PLANT GROWTH REGULATORS PLANT RES INT BV (NL) 2004-11-24 EP claimed
WO-2004075635-A2 CRYSTAL STRUCTURE OF THE TERNARY COMPELEX OF 14-3-3, FUSICOCCIN AND PLASMA MEMBRANE ATPASE AND METHODS FOR DESIGNING NEW HERBICIDES MAX-PLANCK-GESELLSCHAFT ZUR (DE) 2004-09-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174708-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION STUB1, PSMG3, CUL3 YWHAZ 151/4885
US-20090215708-A1 Treatment of Sexual Dysfunction with Proton Pump Agonists GNRHR, HRH2, NSF YWHAZ 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.